Fagron (4A5) Stock Overview
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
4A5 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Fagron NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €22.45 |
| 52 Week High | €22.70 |
| 52 Week Low | €16.30 |
| Beta | 0.25 |
| 1 Month Change | 2.75% |
| 3 Month Change | 16.20% |
| 1 Year Change | 21.75% |
| 3 Year Change | 47.79% |
| 5 Year Change | 20.31% |
| Change since IPO | 124.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4A5 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 3.9% | 1.0% | 1.2% |
| 1Y | 21.7% | 26.8% | 19.0% |
Return vs Industry: 4A5 underperformed the German Healthcare industry which returned 27.4% over the past year.
Return vs Market: 4A5 exceeded the German Market which returned 16.9% over the past year.
Price Volatility
| 4A5 volatility | |
|---|---|
| 4A5 Average Weekly Movement | 3.1% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 4A5 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4A5's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,828 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments.
Fagron NV Fundamentals Summary
| 4A5 fundamental statistics | |
|---|---|
| Market cap | €1.63b |
| Earnings (TTM) | €80.55m |
| Revenue (TTM) | €871.96m |
Is 4A5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4A5 income statement (TTM) | |
|---|---|
| Revenue | €871.96m |
| Cost of Revenue | €476.28m |
| Gross Profit | €395.68m |
| Other Expenses | €315.12m |
| Earnings | €80.55m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 31, 2025
| Earnings per share (EPS) | 1.10 |
| Gross Margin | 45.38% |
| Net Profit Margin | 9.24% |
| Debt/Equity Ratio | 67.8% |
How did 4A5 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/23 06:28 |
| End of Day Share Price | 2025/07/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fagron NV is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Jan Vos | ABN AMRO Bank N.V. |
| Marc Leemans | Banque Degroof |
| Beatrice Fairbairn | Berenberg |